|Former Common name||AML1 KO, Runx1 KO mice|
|H-2 Haplotype||No Data|
|Genotype||a/a B/B C/C|
|Strain development||Developed by Dr. Masanobu Satake, Tohoku University in 1998. A targeting vector containing pgk-neo cassette was transfered into ES cells to relpace exons 4.|
|Strain description||B6.129S4-Runx1<tm1Sata>. Runx1, runt related transcription factor 1 (also called AML1) encodes the DNA binding subunit of the heterodimeric transcription factor. Runx1 is one of the most frequent targets of chromosome translocation associated with several subtypes of human acute myeloid or lymphoblastic leukemia. Mice homozygous for the Runx1 null mutantion die embryonic day 12.5 due to massive hemorrhage in the central nervous system. In fetal livers of mutant embryos, no hematopoieteic cells are generated.|
|Colony maintenance||Backcross to C57BL/6 (Heterozygote x C57BL/6JJcl)|
|Health Report||No Data|
|Symbol name||runt related transcription factor 1|
|Common name||AML1, Cbfa2, Pebp2a2, runt domain, alpha subunit 2|
|Symbol description||No Data|
|Promoter||mouse phosphoglycerate kinase promoter (PGK promoter)|
|Symbol name||neomycin resistance gene (E. coli)|
|Common name||neo; neomycin;|
|Symbol description||No Data|
|References||Oncogene. 1998 Nov 5;17(18):2287-93.
AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene.
|Research applications||Cancer Research,
Cell Biology Research
|Specific Term and Conditions||The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
Oncogene, 17, 2287-2293 (1998).
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use
of it from the DEPOSITOR to avoid possible conflicts with DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a
citation of the following literature designated by the DEPOSITOR is requested.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE,
an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT agrees to include the DEPOSITOR as a co-author in any publications
resulted by the use of the BIOLOGICAL RESOURCE during the first 2 years after deposition by the DEPOSITOR to the RIKEN BRC.
The RECIPIENT should contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
|1||Lab HP (Japanese)|
|2||Genotyping protocol <PCR>|
|Depositor||Satake, Masanobu (Institute of Development, Aging and Cancer, Tohoku University)|
|Strain Status /